Regulated drug work, run on one cloud.

Records a regulator can audit

Veeva starts from a fact of the drug business: a company must be able to show a regulator what happened in every trial, every manufacturing batch and every conversation its sales team had with a doctor. In February 2007, when Veeva launched its first product, much of that work ran on software that an industry analyst later described to TechCrunch as coming from old companies and being hard to use. Peter Gassner, who had just left Salesforce, bet that software built for one regulated industry and delivered from the cloud could become a large business. Nineteen years later Veeva describes itself as the industry cloud for life sciences, made of applications, agents, data and consulting, and it ended fiscal 2026 with 1,552 customers, from the largest drug makers to emerging biotechs.

Starting Veeva, I had the idea or vision you could make very industry-specific software in the cloud and it would be bigger than anyone would have thought.

Peter Gassner · Founder and CEO · Interview with TechCrunch on Veeva's tenth year · 2017-02-25

The belief that set Veeva apart was narrowness. At the start many people told Gassner that focusing on one vertical in the cloud was a bad strategy and that building on someone else's platform, Force.com, was even crazier. Veeva did both, and later moved its products onto its own platform, Vault. In March 2026 Gassner restated the belief for the AI era: AI will not replace core systems of record such as Veeva's, and those systems are going to be used by agents as well as human users. In Signet's reading, that makes the company holding the records and the rules a natural seller of the agents that work on them.

Why now: models that can work inside the records

Two developments made the second stage possible. Large language models matured, and Veeva chose to run them inside its applications rather than beside them. Vault AI agents use models from Anthropic and Amazon hosted on Amazon Bedrock, and the first Veeva AI agents, for CRM and commercial content, were released in December 2025. In May 2026 Veeva announced Falcon, a set of standard agents that carry out multi-step work in clinical, regulatory and safety and escalate to people only for exceptions. Its first targets are trial master file document intake and quality control, health authority correspondence and safety case triage. Falcon MLR, which came with the June 2026 purchase of Copli, already checks promotional content.

One drug's path through Veeva

Take an illustrative Korean biotech running a global trial. When a patient enrolls, the site logs in to Veeva RTSM, randomizes the patient and receives a drug kit assignment, and a supply algorithm decides when to ship more drug to that site. Trial documents flow into Vault eTMF, which keeps the file ready for an inspector, the approach Celltrion adopted in 2019. When the drug moves into production at a contract manufacturer, Veeva Quality Cloud holds the controlled procedures, deviations, training records and QC lab results; Samsung Biologics uses it to bring its clients, contract manufacturers and suppliers into one quality process.

Before launch, medical, legal and regulatory reviewers check each brochure against the approved label, and Falcon MLR now runs the first compliance pass. Sales representatives then plan and record their visits in Vault CRM, where the Agentic Call Report drafts the notes. Human judgement stays at the points regulators care about: a person approves the content, closes the deviation and signs off the validation, and Falcon hands exceptions to people.

Falcon's first clinical, regulatory and safety agents are planned for November 2026, with five early adopters. Until they are live, the agent story rests on Veeva's own tests: Gassner said in August 2026 that early runs already beat the human work they were compared with, and that it was too early to declare success.

The Korea openings sit at three points on this path: trial supply, with six RTSM seats in Seoul and Busan; manufacturing quality, with three pharma quality seats and three for QualityOne; and the commercial seat. In each, the work is to make a regulated process run in software and to show the customer that it holds up in an audit.

Four products behind the Korea hiring

Veeva Quality Cloud is the product most of Veeva's Korean pharma business was built on. It brings controlled documents (QualityDocs), quality events such as deviations and corrective actions (QMS), training records (Training) and the QC laboratory (LIMS) onto one platform that suppliers and contract manufacturers can also use. Veeva says more than 600 biopharma, contract manufacturing, generics and medtech companies use its quality applications. In 2026 Smith+Nephew said it would use it for more than 500,000 annual trainings, and Kindeva, a contract manufacturer, adopted it to bring its sites onto one platform. The Korea solution consultant posting asks for five or more years in the LIMS domain, which points at the newest part of the suite.

Veeva QualityOne takes the same platform to manufacturers outside life sciences: consumer packaged goods, food and beverage and chemicals. It covers QMS, HACCP food safety, document control and training, and lets a brand share audits, nonconformances and supplier corrective action requests with its suppliers and co-manufacturers. Its site says more than 600 companies use it and features Unilever and BASF Personal Care. In Korea the product is new. The 2026 postings describe a founding team aimed at cosmetics brand owners and OEM/ODM makers, food and beverage and specialty chemicals, and list frameworks such as US MoCRA, FSMA, HACCP and CGMP.

Veeva RTSM handles randomization and trial supply. Sites record screening, randomize subjects, get kit assignments and perform emergency unblinding, and supply algorithms keep each site stocked. Veeva acquired the product with Veracity Logic in December 2021, when it had supported more than 175 trials with sites in 60 countries. Veeva sets up and supports every study itself, which explains the Korea seats for technical consultants, validation analysts and customer success associates, and one posting describes migrating legacy RTSM and Windows infrastructure to AWS.

Vault CRM is the commercial product. Field and medical teams plan visits, share approved content and record each interaction with doctors, while Veeva OpenData supplies verified doctor and hospital profiles. Veeva unveiled it in May 2023 to replace Veeva CRM, which ran on Salesforce's platform, and by September 2026 it had more than 190 live customers and global commitments from 14 of the top 20 biopharmas.

Named customers, and what each case shows

The Korean cases show the order in which Veeva entered. Samsung Biologics chose QualityDocs in 2018 and added QMS in 2020 to bring its clients and suppliers into one quality process, and Celltrion implemented Vault eTMF for trial documents in 2019. These are adoption announcements with quotes from the customers. The one number comes from Alvogen Korea, which said in 2021 that Vault MedComms cut its approval and review time by more than 60 percent; that is the customer's own figure. Abroad, Eli Lilly committed to Vault CRM globally in August 2026.

Agents on top of the applications

Falcon MLR comes from Copli, which Veeva bought in June 2026; Veeva says it has the potential to eliminate 70 percent or more of manual MLR labor within five years, a company projection. Study Builder Agent, announced in September 2026, configures EDC and DQS from a study protocol and is planned for early adopters in December 2026.

Each product has a different buyer: the head of quality, the clinical supply lead, the plant or brand quality manager outside pharma, and the commercial leader. The Korea roles split the same way, so a candidate should know which buyer their seat faces and what that buyer is audited on.